News and outlook

• Advanced BioDesign continues to recruit patients for its first-in-man clinical trial “ODYSSEY” of its drug candidate ABD-3001 targeting acute myeloid leukemia (AML) – (EudraCT N°: 2021-003159-4). The first 3 doses were well tolerated by patients (with no dose-limiting toxicity or DLT, and no serious adverse events or SAE). A phase II trial in Europe is planned in AML from the end of 2025. In parallel, ABD is accelerating the preclinical development of a second-generation ALDH inhibitor (ALDHi), ABD-0171. This second lead is currently under development (pharmaceutical scale-up, formulation, clinical proof-of-concept, combination studies, etc). ABD-0171 could be evaluated in a clinical trial in solid tumors from 2026.
• Advanced BioDesign is continuing R&D to consolidate proof-of-concept in cancer indications where medical needs are high, and in particular in solid tumor indications. Investigations are underway in triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), in addition to AML.
• Advanced BioDesign is the winner of the “i-Demo” call for projects launched by BPI as part of “France 2030 plan”: the “ODYSSEY” clinical study will be funded with a €3.2 million grant over 3 years. Today, 30% of its research budget is funded by non-dilutive public aid.